34 research outputs found
Adjunctive Clotiapine for the Management of Delusions in Two Adolescents with Anorexia Nervosa
open7noClotiapine is an atypical antipsychotic indicated for the management of a series of acute
psychotic disorders. The current literature lacks evidence concerning the tolerability and clinical
use of this drug in the management of individuals with anorexia nervosa (AN). In this study, we
report two cases of adolescents with AN, treated with clotiapine. The reason for the administration
of clotiapine was, for both patients, the manifestation of bizarre delusions concerning food and
calories. Patient 1 presented a presyncope after the first dose of clotiapine, and treatment was rapidly
discontinued. Patient 2 was treated with clotiapine for 9 months; doses were titrated from 20 mg/day
to 70 mg/day, with an improvement in the reported delusions, which also enhanced compliance
with psychological and nutritional interventions. EKG, QTc, white blood count, and red blood count
were not relevantly influenced by the introduction of clotiapine in either patient. No extrapyramidal
effect was documented. These reports stress the need for further studies assessing the tolerability
and potential effect of clotiapine in treating adolescents with AN and delusional symptomatology.openJacopo Pruccoli , Giulia Joy Leone, Cristina Di Sarno, Luigi Vetri , Giuseppe Quatrosi ,
Michele Roccella, Antonia ParmeggianiJacopo Pruccoli , Giulia Joy Leone, Cristina Di Sarno, Luigi Vetri , Giuseppe Quatrosi ,
Michele Roccella, Antonia Parmeggian
Comparison of Adaptive Neuroprotective Mechanisms of Sulforaphane and its Interconversion Product Erucin in in Vitro and in Vivo Models of Parkinson's Disease
Several studies suggest that an increase of glutathione (GSH) through activation of the transcriptional nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in the dopaminergic neurons may be a promising neuroprotective strategy in Parkinson's disease (PD). Among Nrf2 activators, isothiocyanate sulforaphane (SFN), derived from precursor glucosinolate present in Brassica vegetables, has gained attention as a potential neuroprotective compound. Bioavailability studies also suggest the contribution of SFN metabolites, including erucin (ERN), to the neuroprotective effects of SFN. Therefore, we compared the in vitro neuroprotective effects of SFN and ERN at the same dose level (5 \u3bcM) and oxidative treatment with 6-hydroxydopamine (6-OHDA) in SH-SY5Y cells. The pretreatment of SH-SY5Y cells with SFN recorded a higher (p < 0.05) active nuclear Nrf2 protein (12.0 \ub1 0.4 vs 8.0 \ub1 0.2 fold increase), mRNA Nrf2 (2.0 \ub1 0.3 vs 1.4 \ub1 0.1 fold increase), total GSH (384.0 \ub1 9.0 vs 256.0 \ub1 8.0 \u3bcM) levels, and resistance to neuronal apoptosis elicited by 6-OHDA compared to ERN. By contrast, the simultaneous treatment of SH-SY5Y cells with either SFN or ERN and 6-OHDA recorded similar neuroprotective effects with both the isothiocyanates (Nrf2 protein 2.2 \ub1 0.2 vs 2.1 \ub1 0.1 and mRNA Nrf2 2.1 \ub1 0.3 vs 1.9 \ub1 0.2 fold increase; total GSH 384.0 \ub1 4.8 vs 352.0 \ub1 6.4 \u3bcM). Finally, in vitro finding was confirmed in a 6-OHDA-PD mouse model. The metabolic oxidation of ERN to SFN could account for their similar neuroprotective effects in vivo, raising the possibility of using vegetables containing a precursor of ERN for systemic antioxidant benefits in a similar manner to SFN
MIS-C Treatment: Is IVIG Always Necessary?
Background: MIS-C is a potentially severe inflammatory syndrome associated with SARS-CoV-2 exposure. Intravenous immunoglobulin (IVIG) is considered the first-tier therapy, but it implies infusion of large fluid volumes that may worsen cardiac function. Patients and Methods: Since April 2020, we have developed a treatment protocol that avoids the infusion of IVIG as first-line therapy in the early phase of MIS-C. In this study, we retrospectively analyzed a cohort of consecutive patients treated according to this protocol between 01/04/2020 and 01/04/2021. Results: In the last year, 31 patients have been treated according to the protocol: 25 with high-dose pulse MP (10 mg/kg) and 6 with 2 mg/kg. 67.7% of the patients responded to the initial treatment, while the others needed a step-up, either with Anakinra (25.8%) or with MP dose increase (6.5%). IVIG was administered in four patients. Overall, only one patient (3.2%) needed ICU admission and inotropic support; one patient developed a small coronary artery aneurysm. Conclusions: Timely start of MP therapy and careful fluid management might improve the outcomes of MIS-C patients
First diagnosis of multisystem inflammatory syndrome in children (MIS-C): an analysis of PoCUS findings in the ED
Children with multisystem inflammatory syndrome (MIS-C) tend to develop a clinical condition of fluid overload due both to contractile cardiac pump deficit and to endotheliitis with subsequent capillary leak syndrome. In this context, the ability of point-of-care ultrasound (PoCUS) to simultaneously explore multiple systems and detect polyserositis could promote adequate therapeutic management of fluid balance. We describe the PoCUS findings in a case-series of MIS-C patients admitted to the Emergency Department. At admission 10/11 patients showed satisfactory clinical condition without signs and symptoms suggestive for cardiovascular impairment/shock, but PoCUS showed pathological findings in 11/11 (100%). In particular, according to Rapid Ultrasound in SHock (RUSH) protocol, cardiac hypokinesis was detected in 5/11 (45%) and inferior vena cava dilatation in 3/11 (27%). Peritoneal fluid was reported in 6/11 cases (54%). Lung ultrasound (LUS) evaluation revealed an interstitial syndrome in 11/11 (100%), mainly localized in posterior basal lung segments. We suggest PoCUS as a useful tool in the first evaluation of children with suspected MIS-C for the initial therapeutic management and the following monitoring of possible cardiovascular deterioration
Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study
Background: Many aspects of SARS-CoV-2 infection in children and adolescents
remain unclear and optimal treatment is debated. The objective of our study was
to investigate epidemiological, clinical and therapeutic characteristics of pediatric
SARS-CoV-2 infection, focusing on risk factors for complicated and critical disease.
Methods: The present multicenter Italian study was promoted by the Italian Society
of Pediatric Infectious Diseases, involving both pediatric hospitals and general
pediatricians/family doctors. All subjects under 18 years of age with documented
SARS-CoV-2 infection and referred to the coordinating center were enrolled from
March 2020.
Results: As of 15 September 2020, 759 children were enrolled (median age 7.2 years,
IQR 1.4; 12.4). Among the 688 symptomatic children, fever was the most common
symptom (81.9%). Barely 47% of children were hospitalized for COVID-19. Age was
inversely related to hospital admission (p < 0.01) and linearly to length of stay (p = 0.014).
One hundred forty-nine children (19.6%) developed complications. Comorbidities were
risk factors for complications (p < 0.001). Viral coinfections, underlying clinical conditions,
age 5\u20139 years and lymphopenia were statistically related to ICU admission (p < 0.05).
Garazzino et al. SARS-CoV-2 in Children and Adolescents
Conclusions: Complications of COVID-19 in children are related to comorbidities and
increase with age. Viral co-infections are additional risk factors for disease progression
and multisystem inflammatory syndrome temporarily related to COVID-19 (MIS-C) for
ICU admission
COVID-19 in Infants Less than 3 Months: Severe or Not Severe Disease?
Compared to adults, severe or fatal COVID-19 disease is much less common in children. However, a higher risk for progression has been reported in infants. Different pediatric COVID-19 severity scores are reported in the literature